{"id":"spd476-4-8-g","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, SPD476 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.","oneSentence":"SPD476 is a small molecule drug that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:35:44.205Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT00545740","phase":"PHASE3","title":"Prevention of Recurrence of Diverticulitis","status":"COMPLETED","sponsor":"Shire","startDate":"2007-11-28","conditions":"Diverticulitis","enrollment":590},{"nctId":"NCT00545103","phase":"PHASE3","title":"Prevention of Recurrence of Diverticulitis","status":"COMPLETED","sponsor":"Shire","startDate":"2007-12-06","conditions":"Diverticulitis","enrollment":592},{"nctId":"NCT00503243","phase":"PHASE3","title":"Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis","status":"COMPLETED","sponsor":"Shire","startDate":"2003-09-30","conditions":"Colitis, Ulcerative","enrollment":280}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lialda, MMX™ mesalazine"],"phase":"phase_3","status":"active","brandName":"SPD476 (4.8 g)","genericName":"SPD476 (4.8 g)","companyName":"Shire","companyId":"shire","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SPD476 is a medication being studied in clinical trials for the prevention of recurrence of diverticulitis, as well as for the treatment of colitis and ulcerative colitis. The medication has been tested in doses of 1.2g, 2.4g, and 4.8g in clinical trials.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}